ORYZF (Oryzon Genomics) Beginning Cash Position: $0.00 Mil (As of Mar. 2026)


ORYZF Oryzon Genomics SA ORYZF
31 GF Score
Price $3.66
View Full Analysis

What is Oryzon Genomics Beginning Cash Position?

Oryzon Genomics ORYZF 31 Beginning Cash Position is $0.00 Mil as of Mar. 2026. GuruFocus rates ORYZF with a GF Score™ of 31/100.

Oryzon Genomics's Beginning Cash Position for the quarter that ended in Mar. 2026 was $0.00 Mil.

Oryzon Genomics's annual Beginning Cash Position declined from Dec. 2023 ($23.56 Mil) to Dec. 2024 ($12.76 Mil) and declined from Dec. 2024 ($12.76 Mil) to Dec. 2025 ($6.60 Mil).

Oryzon Genomics Beginning Cash Position Related Terms

Oryzon Genomics Beginning Cash Position Historical Data

* Premium members only.

The historical data trend for Oryzon Genomics's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Oryzon Genomics Beginning Cash Position Chart

Oryzon Genomics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beginning Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 44.84 30.80 23.56 12.76 6.60

Oryzon Genomics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beginning Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
ORYZF
31GF Score
Oryzon Genomics SA ORYZF
Beginning Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Oryzon Genomics Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

What does a Beginning Cash Position of $0.00 Mil mean?
Oryzon Genomics (ORYZF) has a Beginning Cash Position of $0.00 Mil as of Mar. 2026. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Oryzon Genomics and its competitors.
Is Oryzon Genomics' Beginning Cash Position too high?
Oryzon Genomics' current Beginning Cash Position is $0.00 Mil. Overall, Oryzon Genomics has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Oryzon Genomics' Beginning Cash Position compare to VRTX and REGN?
Oryzon Genomics' Beginning Cash Position of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beginning Cash Position for a Biotechnology company?
A good Beginning Cash Position depends on the Biotechnology industry context. However, Beginning Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beginning Cash Position mean?
A high Beginning Cash Position can signal that a stock is expensive relative to its fundamentals. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Oryzon Genomics and its competitors. Oryzon Genomics's current Beginning Cash Position is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oryzon Genomics stock overvalued right now?
Oryzon Genomics (ORYZF) has a current Beginning Cash Position of $0.00 Mil. The current Beginning Cash Position is $0.00 Mil. Oryzon Genomics' overall GF Score™ is 31/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beginning Cash Position calculated?
Beginning Cash Position is calculated from a company's financial statements. For Oryzon Genomics (ORYZF), the current Beginning Cash Position is $0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Oryzon Genomics Business Description

Other Exchanges 0RDB:UKORY:SpainORN:Germany
Address Sant Ferran 74, Cornellà de Llobregat, Barcelona, ESP, 08940
Oryzon Genomics SA is a clinical stage biopharmaceutical company and engaged in the development of epigenetics-based therapeutics. It is engaged in the field of epigenetic medicine and in the development of therapeutic, biological solutions for cancer and neurodegenerative diseases.
31GF Score

Get the complete analysis for ORYZF

Beginning Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.66
Price